Struggling gene sequencer Pacific Biosciences signed a diagnostics product-development deal with industry giant Roche worth as much as $75 million.
Struggling gene sequencer Pacific Biosciences saw its stock rocket upward in the wake of a diagnostics development deal with industry giant Roche that's worth as much as $75 million, closing at $5.98 on Sept. 25, a jump of more than 72.8%.
Roche's massive diagnostics division has signed on with yet another development partner: California's Pacific Biosciences, which focuses on gene sequencing. The pair will develop diagnostics products for clinical research.
In the biotech game, New York City doesn't hold a candle to Boston or San Francisco. But if anyone can change that perception, perhaps it's Eric Schadt, the chief scientist of Pacific Biosciences (
The math on sequencing's growing reach is pretty simple. In 2009, a few dozen genomes were sequenced. Last year the genes of some 1,700 people were sequenced. This year, analysts say the number will
Pacific Biosciences ($PACB) wants to offer users of its sequencing machine new cloud computing capabilities amid struggles to hit sales targets for its cutting edge system for quickly and cheaply...
Creating a company on the bleeding edge of a new technology can cut both ways. After the initial demand for its highly touted sequencing tech fell short of expectations, Menlo Park, CA-based Pacific
With the commercial release of Pacific Biosciences' third-generation sequencer in April come new opportunities for software vendors to provide tools to enhance the utility of the data provided by the
Dr. Eric E. Schadt (photo), a rock star of sorts in genetics circles and chief scientist at Pacific Biosciences ($PACB), is set to lead a new genomics research group at Mount Sinai in New York. Menlo
This week Pacific Biosciences--the biotech superstar that has raised hundreds of millions in venture capital and launched an IPO--started shipping its PacBio RS system. According to a release, the